EYA2 and leukemia: Other dysregulated pathways and potential therapeutic targets detected in PLZF-RARα leukemia (which, however, were not further investigated) included upregulation of CRABPI (cellular retinoic acid binding protein 1 [106]), EYA2 (EYA transcriptional coactivator and phosphatase 2 [107]), and USP37 (ubiquitin-specific peptidase 37 [108]).